500770-67-2 Usage
Description
BOC-(S)-3-AMINO-3-(3-THIENYL)-PROPIONIC ACID is a specialized amino acid derivative characterized by the presence of a t-butyloxycarbonyl (BOC) protecting group and a 3-thienyl aromatic ring. This chiral compound, with its (S) configuration, is pivotal in the synthesis of pharmaceuticals and bioactive molecules due to its unique structural features and reactivity.
Uses
Used in Pharmaceutical Synthesis:
BOC-(S)-3-AMINO-3-(3-THIENYL)-PROPIONIC ACID serves as a key building block in the creation of various pharmaceuticals. Its BOC group protects the amino functionality during synthetic processes, preventing unwanted side reactions and ensuring the integrity of the final product. The 3-thienyl moiety contributes to the compound's bioactivity, making it a valuable component in the development of new drugs.
Used in Bioactive Compounds Synthesis:
In the field of bioactive compounds, BOC-(S)-3-AMINO-3-(3-THIENYL)-PROPIONIC ACID is utilized for its potential to enhance the biological activity of synthesized molecules. The presence of the 3-thienyl ring, known for its aromatic properties and sulfur content, can impart specific pharmacological effects, making it a sought-after component in the design of bioactive molecules with targeted therapeutic applications.
Used in Chiral Synthesis:
The (S) configuration of BOC-(S)-3-AMINO-3-(3-THIENYL)-PROPIONIC ACID makes it an essential component in chiral synthesis, where the stereochemistry of a molecule is critical to its biological activity and selectivity. This enantiomer is particularly useful in the development of enantioselective catalysts and in asymmetric synthesis processes, contributing to the creation of pharmaceuticals with improved efficacy and reduced side effects.
Used in Research and Development:
In academic and industrial research settings, BOC-(S)-3-AMINO-3-(3-THIENYL)-PROPIONIC ACID is employed as a versatile reagent for exploring new chemical reactions and synthetic pathways. Its unique structural elements allow researchers to investigate the effects of protecting groups and heteroaromatic rings on reaction outcomes, furthering the understanding of organic chemistry and its applications in drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 500770-67-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,0,7,7 and 0 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 500770-67:
(8*5)+(7*0)+(6*0)+(5*7)+(4*7)+(3*0)+(2*6)+(1*7)=122
122 % 10 = 2
So 500770-67-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H17NO4S/c1-12(2,3)17-11(16)13-9(6-10(14)15)8-4-5-18-7-8/h4-5,7,9H,6H2,1-3H3,(H,13,16)(H,14,15)
500770-67-2Relevant articles and documents
AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS
-
, (2019/10/04)
Provided herein are amino-benzoisothiazole and benzoisothiadiazole amide compounds. In particular, provided herein are compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, retinal diseases such as acute macular degeneration (AMD) and diabetic macular edema (DME), diseases and conditions characterized by inflammatory processes, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. Also provided are compositions (e.g., pharmaceutical compositions) comprising the compounds provided herein.
2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS
-
Page/Page column 33, (2010/02/08)
The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV having the formula I: (I) The invention furthermore relates to pharmaceutical compositions comprising the compounds and the use of such compounds for the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.
